
    
      Non-probability sampling: The study population consists of adult patients over the age of 18
      affected by CHC who were previously treated for the first time with Peg-IFN alfa-2b plus
      ribavirin and achieved end-of-treatment response. Five hundred ninety patients must be
      recruited in order to evaluate the objectives of the study. The patients must meet all
      inclusion criteria and not meet any of the exclusion criteria in order to be included in the
      study.
    
  